Drug Profile


Alternative Names: (-)dOTC; ATC; AVX-754; BCH 10618; SPD-754

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Novita Healthcare
  • Class Antiretrovirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 04 Feb 2016 Phase-III development is ongoing in Australia, Canada, USA, South America, Europe, Africa, Asia and Israel
  • 20 Jun 2013 Avexa signs binding term sheet with Link Healthcare relating to development, registration, and commercialisation of apricitabine worldwide (including North America and Europe)
  • 21 Feb 2013 Avexa announces option commercialisation agreements upon completion of clinical and regulatory development of apricitabine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top